Andere Sprachen Ocugen, Inc.

Aktien

A2PSZH

US67577C1053

OCGN

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
1,28 ^USD	+8,47 %		-3,03 %	+122,61 %

23.04.	OCUGEN, INC. : Chardan Research bekräftigt seine Kaufempfehlung	ZM
23.04.	OCUGEN, INC. : Chardan Research bekräftigt seine Kaufempfehlung	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN	27.04.
ROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN	27.04.
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting	26.04.
IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm	23.04.
Pomerantz Law Firm Announces the Filing of a Class Action Against Ocugen, Inc. - OCGN	20.04.
OCGN Bronstein, Gewirtz & Grossman LLC Announces that Ocugen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!	19.04.
Ocugen Completes Dosing in Trial of Gene Therapy for Macular Degeneration	19.04.
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy	19.04.
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410 --A Modifier Gene Therapy	19.04.
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen	18.04.
ROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN	18.04.
IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm	17.04.
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN	17.04.
Ocugen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	16.04.
OCUGEN TO PARTICIPATE IN FIRESIDE CHAT AT THE EMERGING GROWTH VIRTUAL HEALTHCARE EQUITY CONFERENCE, PRESENTED BY NOBLE CAPITAL MARKETS	15.04.
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm	15.04.
Law Offices of Howard G. Smith Announces Investigation of Ocugen, Inc. (OCGN) on Behalf of Investors	12.04.
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Ocugen, Inc. - OCGN	12.04.
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets	12.04.
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen	12.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Ocugen, Inc.

Aktien

A2PSZH

US67577C1053

OCGN

Andere Sprachen

Filter